UA31530U - Способ коррекции метаболических нарушений у больных раком прямой кишки - Google Patents
Способ коррекции метаболических нарушений у больных раком прямой кишки Download PDFInfo
- Publication number
- UA31530U UA31530U UAU200714306U UAU200714306U UA31530U UA 31530 U UA31530 U UA 31530U UA U200714306 U UAU200714306 U UA U200714306U UA U200714306 U UAU200714306 U UA U200714306U UA 31530 U UA31530 U UA 31530U
- Authority
- UA
- Ukraine
- Prior art keywords
- patients
- metabolic disorders
- day
- activity
- correction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 26
- 206010038038 rectal cancer Diseases 0.000 title claims abstract description 12
- 208000015634 Rectal Neoplasms Diseases 0.000 title claims abstract description 10
- 201000001275 rectum cancer Diseases 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 33
- 229920005617 polyoxidonium Polymers 0.000 claims abstract description 21
- AEKLPNAELPOQBI-RHLRHBBGSA-L disodium butanedioate (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].C(CCC(=O)[O-])(=O)[O-].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+] AEKLPNAELPOQBI-RHLRHBBGSA-L 0.000 claims abstract description 14
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- RVEWUBJVAHOGKA-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;2-aminopentanedioic acid Chemical compound OC(=O)C(N)CCC(O)=O.OC(=O)C(N)CCCN=C(N)N RVEWUBJVAHOGKA-UHFFFAOYSA-N 0.000 claims description 19
- 238000012876 topography Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 description 23
- 238000002512 chemotherapy Methods 0.000 description 17
- 229940118019 malondialdehyde Drugs 0.000 description 16
- 230000002503 metabolic effect Effects 0.000 description 16
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 description 13
- 108010012715 Superoxide dismutase Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000003859 lipid peroxidation Effects 0.000 description 7
- 230000013632 homeostatic process Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 230000035987 intoxication Effects 0.000 description 5
- 231100000566 intoxication Toxicity 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- USMZEYPOTJAYPT-LRROQMAJSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 USMZEYPOTJAYPT-LRROQMAJSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000686 immunotropic effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ коррекции метаболических нарушений у больных раком прямой кишки включает применение энтеросорбентов, глутаргина и реамберина, причем дополнительно больным вводят полиоксидоний внутримышечно по 6 мг 1 раз в сутки через день, всего 6-10 инъекций, в зависимости от достигнутого эффекта.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200714306U UA31530U (ru) | 2007-12-19 | 2007-12-19 | Способ коррекции метаболических нарушений у больных раком прямой кишки |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200714306U UA31530U (ru) | 2007-12-19 | 2007-12-19 | Способ коррекции метаболических нарушений у больных раком прямой кишки |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA31530U true UA31530U (ru) | 2008-04-10 |
Family
ID=39819573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU200714306U UA31530U (ru) | 2007-12-19 | 2007-12-19 | Способ коррекции метаболических нарушений у больных раком прямой кишки |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA31530U (ru) |
-
2007
- 2007-12-19 UA UAU200714306U patent/UA31530U/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7125836B2 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
| US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| Wang et al. | Copper‐Based Composites Nanoparticles Improve Triple‐Negative Breast Cancer Treatment with Induction of Apoptosis‐Cuproptosis and Immune Activation | |
| CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
| CA3213804A1 (en) | Wee1 compound for treating uterine serous carcinoma | |
| UA31530U (ru) | Способ коррекции метаболических нарушений у больных раком прямой кишки | |
| RU2524309C1 (ru) | Способ выбора тактики лечения местно-распространенного рака предстательной железы | |
| TWI707681B (zh) | 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途 | |
| CN111939159A (zh) | Nsc 23766辅助肿瘤放射治疗的用途 | |
| CN110227083A (zh) | 一种含氯化钆和双胍类降糖药的药物组合物及其用途 | |
| US20100029590A1 (en) | Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt | |
| CN100455289C (zh) | 孟德拉明类抗癌药 | |
| CN113425723B (zh) | Pim1小分子抑制剂在制备防治强直性脊柱炎产品中的应用 | |
| CN113244208B (zh) | Hpa在制备治疗非酒精性脂肪性肝病药物中的应用 | |
| CN111407748B (zh) | 酪醇在制备治疗脑胶质瘤的药物中的应用 | |
| TW201429479A (zh) | 褐藻醣膠對於治療惡病質及癌症之應用 | |
| UA17881U (en) | Method for correcting metabolic disorders in patients with early forms of rectal cancer | |
| Clifford et al. | Dimethyl myleran therapy combined with abdominal aortic occlusion | |
| UA14580U (en) | Method for correcting metabolic disorders in treatment of early stages of rectal cancer | |
| Tadikamalla | Implications of Chemotherapy, Radiation therapy, and Surgical treatment in Oral Cancer | |
| RU2211035C1 (ru) | Противотуберкулезный препарат | |
| CN114748513A (zh) | 肠道罗斯拜瑞氏菌在制备肿瘤的放射增敏剂中的用途 | |
| RU2063770C1 (ru) | Способ лечения гнойно-воспалительных заболеваний легких | |
| US20070154567A1 (en) | Use of mercury to treat cancer | |
| RU2134589C1 (ru) | Способ лечения первичного рака печени и набор для лечения первичного рака печени |